X
-linked retinitis pigmentosa (XLRP) includes some of the earliest onset and rapidly progressive forms of inherited retinal degenerations, and accounts for 6% -20% of all cases of retinitis pigmentosa (Fishman 1978; Jay 1982; Breuer et al. 2002) . XLRP has been genetically mapped to six loci (RP2, RP3, RP6, RP23, RP24, and RP34); of these, RP3, which is associated with mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene, is the predominant subtype (Meindl et al. 1996; Roepman et al. 1996) . Indeed, mutations in RPGR are found in .70% of families affected by XLRP and 15% of simplex retinitis pigmentosa cases (Bader et al. 2003; Sharon et al. 2003; Pelletier et al. 2007; Branham et al. 2012) . Over the past decade, substantial effort has been dedicated to unveiling RPGR's function in photoreceptors, identifying novel mutations and the spectrum of disease phenotypes in humans, and characterizing small and large animal models of RPGR-XLRP that could be used to test novel therapeutic approaches. This review will primarily focus on the results of the preclinical studies conducted in canine models, as these provide strong evidence that a corrective gene therapy for XLRP may become a reality in the not-so-distant future.
RPGR AND ITS ROLES IN THE PHOTORECEPTOR CONNECTING CILIUM
The RPGR gene (172 kb) was initially described as containing 19 exons, and mutations in RPGR ex1-19 accounted for only 15% -20% of XLRP patients (Meindl et al. 1996) . Subsequently, an alternatively spliced carboxy-terminal exon called ORF15 was identified and found to be a hot spot for microdeletions, frameshift mutations, and premature stop mutations . Of the more than 350 RPGR mutations reported to date, .55% are found in exon ORF15 (see http://rpgr.hgu.mrc.ac.uk).
Among the different splice variants Neidhardt et al. 2007; Schmid et al. 2010) , RPGR ex1-ORF15 and constitutive RPGR ex1-19 are the most abundantly expressed RPGR isoforms in the retina. Both proteins have been immunolocalized to photoreceptor connecting cilium of both rods and cones (Hong et al. 2003; Wright et al. 2011) . One group found RPGR ex1-ORF15 in bovine and human photoreceptor outer segments (Roepman et al. 2000; Mavlyutov et al. 2002) , although this was later disputed (Hong et al. 2003) . The different temporal pattern of retinal expression of these two isoforms suggests that RPGR ex1-19 may play a role in photoreceptor development whereas RPGR ex1-ORF15 may be necessary for maintaining the integrity of mature photoreceptors . The constitutive human RPGR ex1-19 isoform encodes an 815 amino acid protein (MW: 90 -100 kDa) that is widely expressed, whereas the full-length human RPGR ex1-ORF15 isoform, which encodes a 1152 amino acid, soluble protein (MW: 200-220 kDa), has been found predominantly in photoreceptors.
Both isoforms contain a common aminoterminal RCC1-like domain (Meindl et al. 1996) (encoded by exons 2 to 11), which has recently been shown to play the role of a guanine nucleotide exchange factor (GEF) by directly interacting with the GDP-bound form of the small GTPase RAB8A (Murga-Zamalloa et al. 2010a ). RPGR has also been shown to interact directly or via molecular complexes with the following proteins: PDE6d (Linari et al. 1999 ); a number of ciliary proteins, including RPGRinteracting protein 1 (RPGRIP1) (Boylan and Wright 2000; Roepman et al. 2000; Hong et al. 2001) ; the nephrocystins NPHP1 (Murga-Zamalloa et al. 2010b), NPHP4 (Murga-Zamalloa et al. 2010b ), NPHP5/IQCB1 (Otto et al. 2005) , NPHP6/CEP290 (Chang et al. 2006) , and NPHP8/RPGRIP1L (Khanna et al. 2009 ); the chromosome-associated proteins SMC1 and SMC3 ; the centrosomal protein NPM1 ; and proteins associated with intraflagellar transport (Tg737/ Polaris/IFT88) and microtubule motors (dynactin subunits, kinesin-II) . Exon ORF15 encodes for a highly repetitive, glutamic acid-rich region whose function is currently unknown, yet its carboxyl terminus has been recently shown to interact with whirlin, which is a member of the Usher interactome . Localization of RPGR to the sensory cilia of photoreceptors (Hong et al. 2003) and its interaction with numerous complexes involved in protein transportation suggest that RPGR plays a role in regulating protein trafficking between the inner and outer segments at the level of the connecting cilium; however, its exact molecular function is still poorly understood.
Recent reports have suggested that RPGR may contribute to the biogenesis and maintenance of photoreceptor cilia and the transitional zone of motile cilia (Murga-Zamalloa et al. 2010a; Gakovic et al. 2011; Ghosh et al. 2011 ). This role is consistent with the occurrence of hearing dysfunction, respiratory infections, and cilia dyskinesis in some rare cases of syndromic RPGR-XLRP (van Dorp et al. 1992; Iannaccone et al. 2003; Koenekoop et al. 2003; Zito et al. 2003; Iannaccone et al. 2004; Moore et al. 2006; Bukowy-Bieryllo et al. 2013 ).
RETINAL DEGENERATION PHENOTYPE OF XLRP PATIENTS WITH RPGR MUTATIONS
A range of clinical diagnoses has been associated with RPGR mutations that cause progressive retinal degeneration of photoreceptors. RPGRassociated retinal degeneration most commonly presents in males of XLRP families or in simplex males as early loss of night vision and peripheral vision, abnormal electroretinograms, and relatively better retention of central vision in younger patients (Meindl et al. 1996; Roepman et al. 1996; Vervoort et al. 2000; Sandberg et al. 2007; Zahid et al. 2013 ). Less commonly, there is early involvement of the fovea and loss of visual acuity. Depending on the degree of abnormality in retina-wide measurements of cone versus rod function, clinical diagnoses have included Xlinked cone-rod dystrophy, cone dystrophy, or macular degeneration (Mears et al. 2000; Ayyagari et al. 2002; Demirci et al. 2002; Yang et al. 2002; Ebenezer et al. 2005; Pelletier et al. 2007; Thiadens et al. 2011; Beltran et al. 2012) . Retinally colocalized measures of function have often shown both rod and cone loss (Jacobson et al. 1997; Lorenz et al. 2003; Huang et al. 2012 ) consistent with expression of the RPGR gene product in rod and cone cilia (Hong et al. 2000 (Hong et al. , 2003 Roepman et al. 2000; Khanna et al. 2005; Shu et al. 2005) . High allelic heterogeneity has been implied as cause for the spectrum of severity and phenotypes encountered between families carrying different RPGR mutations, and there is evidence that genetic modifiers may contribute to intra-familial phenotypic divergence (Keith et al. 1991; Walia et al. 2008; Ruddle et al. 2009; Fahim et al. 2011) .
Carrier females with RPGR mutations also show a wide spectrum of retinal disease expression ranging from asymptomatic with normal electrophysiological and psychophysical test results to very severe retina-wide disease (Andreasson et al. 1997; Jacobson et al. 1997; Weleber et al. 1997; Bauer et al. 1998; Fishman et al. 1998; Flaxel et al. 1999; Ayyagari et al. 2002; Lorenz et al. 2003; Ebenezer et al. 2005; Jin et al. 2006; Ruddle et al. 2009; Thiadens et al. 2011) . There tends to be significant interocular asymmetry of disease severity in most carriers (Jacobson et al. 1989; Weleber et al. 1997; Fishman et al. 1998; Lorenz et al. 2003; Ebenezer et al. 2005) . A distinct golden tapetal-like reflex, hypothesized to be located at cone inner segments (Cideciyan and Jacobson 1994) , or peripheral photoreceptor outer segments (Berendschot et al. 1996) , has been variably described in a subset of female carriers of RPGR mutations (Andreasson et al. 1997; Jacobson et al. 1997; Weleber et al. 1997; Bauer et al. 1998; Fishman et al. 1998; Flaxel et al. 1999; Ayyagari et al. 2002; Lorenz et al. 2003; Ebenezer et al. 2005; Jin et al. 2006; Ruddle et al. 2009; Thiadens et al. 2011) .
ANIMAL MODELS OF RPGR-XLRP

Murine Models
The description of the phenotypes of several mouse models of RPGR disease, including XLRP (Hong et al. 2000 (Hong et al. , 2004 Brunner et al. 2010; Wright et al. 2011; Huang et al. 2012; Thompson et al. 2012 ) and cone-rod dystrophy (Brunner et al. 2010) , have been published. Evidence that mice sharing the same RPGR mutation but on a different genetic background can express a different disease phenotype further highlights the potential role of genetic modifiers (Brunner et al. 2010) . Overexpression of the RPGR ex1-19 isoform in photoreceptor cells of transgenic mice leads to early onset (2 months of age) degeneration, whereas no retinal alterations are associated with overexpression of the RPGR ex1-ORF15 isoform ). This finding further supports the claim that the severe phenotype described in a transgenic mouse expressing a truncated RPGR isoform is caused by a toxic gain-of-function and not to the overexpression of the transgene (Hong et al. 2004) . With the exception of this transgenic model that shows rapid kinetics of photoreceptor loss, the other RPGR mutant mice, including the naturally occurring Rd9 mouse (Thompson et al. 2012 ) that could be used to test a gene augmentation therapy strategy, show a slowly progressive photoreceptor degeneration resulting in retention of .50% outer nuclear layer thickness by 2 years of age (summarized in Huang et al. 2012, Supplementary Table S1 , see http://www.iovs.org/lookup/ suppl/doi:10.1167/iovs.12-10070/-/DCSupple mental).
Canine Models
To date, the XLPRA1 and XLPRA2 dogs are the only identified large animal models of RPGR-XLRP. Although both diseases are caused by nearby microdeletions in the same exon ORF15, they show distinct ages of onset, rates of progression, and spatiotemporal distribution of retinal degeneration.
In XLPRA1, a five nucleotide deletion in exon ORF15 (c.1028 -1032delGAGAA; GeneBank accession no. AF385621) introduces an immediate premature stop codon, and the putative protein has 230 amino acids truncated at its carboxyl-terminal end . This deletion causes a rod-cone degeneration detectable by histology and electroretinogram in juvenile hemizygote male dogs (approximately one year of age) that progresses from the peripheral to the central retina (Zeiss et al. 1999; Beltran et al. 2012) . Even though the research colony has been established from a single affected male, the extent of severity of the retinal changes, and their rate of progression varies from one individual to another even in animals of the same age (Zeiss et al. 1999; Guyon et al. 2007; Beltran et al. 2012) , suggesting that genetic modifiers which have been implicated in humans with RPGR-XLRP (Fahim et al. 2011 ) may also be responsible for this variability in disease phenotype. As a result of random X-inactivation (also called lyonization), heterozygous female dogs undergo a patchy form of retinal degeneration (Zeiss et al. 1999; Beltran et al. 2009 ) that is the result of loss of photoreceptors that are clonally derived from a progenitor cell expressing the mutant XLPRA1 allele. This mosaic pattern of retinal degeneration, which is histologically detectable at 1.4 yr and is still apparent in 7.8-yr-old dogs, resembles the phenotype reported in human XLRP carriers (Szamier and Berson 1985; Jacobson et al. 1997; Aguirre et al. 2002; Vajaranant et al. 2002) .
A second form of canine RPGR-XLRP, termed XLPRA2, is caused by a two nucleotide deletion in ORF15 (c.1084 -1085delGA) . This microdeletion introduces a frameshift followed by a premature stop codon. The putative protein includes 34 additional basic residues and an increased isoelectric point (4.30 vs. 4.01). XLPRA2 retinas undergo early (4 weeks of age) disorganization of photoreceptor outer segments, which is followed by increased cell death that peaks at about 7 weeks of age before returning, at 12 weeks, to a reduced yet constant rate. These photoreceptor cell death kinetics result in rapid outer nuclear layer thinning, that leads to an average thickness of three rows of nuclei by 41 weeks of age. Early cone disease has been shown to occur in the newly discovered canine fovea-like area (Beltran et al. 2014a ). Mislocalization of rod opsin, short-wavelength (blue) cone opsin, and middle/long-wavelength (red/green) opsin are other early events that suggest that this canine ciliopathy affects all populations of photoreceptors. Similar evidence for altered protein trafficking through the connecting cilium has been reported in murine models (Hong et al. 2000 (Hong et al. , 2005 Brunner et al. 2010; Wright et al. 2011; Thompson et al. 2012) , and in a carrier patient of XLRP (Adamian et al. 2006) . Initiation of photoreceptor loss is accompanied by early retinal remodeling events such as rod neurite sprouting, retraction of rod bipolar dendrites, and Müller cell gliosis. Subsequently, other inner retinal remodeling events, including altered labeling of cell-specific markers of horizontal and amacrine cells, and loss of normal inner plexiform lamination follows (Beltran et al. 2006) . Despite the severe progression of the disease, particularly in the central (visual streak) area (Beltran et al. 2012 ), dogs at 41 weeks of age retain sufficient rod-and cone-mediated visual function to navigate without difficulties in an obstacle avoidance course (WA Beltran, unpubl.) . Similarly to XLPRA1 carriers, XLPRA2 heterozygous mutant dogs undergo random Xinactivation during embryogenesis that results in a patchy form of retinal degeneration (Fig. 1) . However, unlike XLPRA1, the focal areas of cell loss do not persist. Indeed, improved outer nuclear layer lamination, loss of opsin mislocalization, and improved morphology of the outer plexiform layer and rod bipolar cell dendrites in older carriers suggests that retinal plasticity in the young XLPRA2 carriers allows tangential displacement of remaining (nonmutant) photoreceptors in the depleted foci, and rewiring with postreceptoral neurons ). Similar lateral dispersion of photoreceptors following focal laser damage has been W.A. Beltran et al. shown in the nonhuman primate retina (Strazzeri et al. 2014) .
Earlier on, we speculated that the more severe disease phenotype observed in the XLPRA2 model could be caused by a toxic gain-of-function, whereas the slower progression and delayed onset seen in XLPRA1 might be explained by a loss-of-function mechanism. These hypotheses led us to initially develop a gene augmentation strategy for the XLPRA1 disease, while preparing for the potential need to combine an alleleindependent gene knockdown and a hardened (resistant) gene replacement approach to correct the XLPRA2 phenotype (see below).
OUTCOME MEASURES OF PRECLINICAL EFFICACY
Detailed analysis of the spatiotemporal features of the two canine diseases and development of staging classifications allowed establishment of outcome measures of therapeutic intervention. These are listed in Table 1 .
THERAPEUTIC INTERVENTIONS: PROOF OF CONCEPT STUDIES IN CANINE MODELS OF RPGR-XLRP
Note: All studies reported below were carried out after approval by the University of Pennsyl- Following successful demonstration of neuroprotection therapy in the rcd1 dog model of autosomal recessive retinitis pigmentosa (PDE6B mutation) (Tao et al. 2002) , we examined whether single or repeated intravitreal injections of recombinant human ciliary neurotrophic factor (CNTF) would also modify the course of retinal degeneration in the XLPRA2 dog. Our results (Beltran et al. 2007 ) failed to demonstrate any positive outcome even when the compound was delivered before the peak of rod loss. However, we observed an increased number of rod opsin-positive cells in the peripheral retina, suggesting the potential for CNTF-mediated photoreceptor cell proliferation in the early postnatal XLPRA2 retina.
Gene Transfer Considerations: Choice of Viral Vector, Promoters, Route of Delivery
Among the various chimeric serotypes of recombinant adeno-associated viral (AAV) vectors previously used for gene transfer to the canine retina (Beltran 2009 ), we selected the AAV2/5 serotype, as it had been shown in dogs to infect both rods and cones (Weber et al. 2003; Komaromy et al. 2008; Petersen-Jones et al. 2009; Beltran et al. 2010) . Photoreceptorspecific promoters that would restrict transgene expression to either rods (mOP, a 476 nt segment of the proximal mouse opsin promoter), or rods and cones (hGRK1, a 292 nt segment of the human G-protein-coupled receptor kinase 1 promoter; hIRBP, a 235 nt segment of the human interphotoreceptor binding protein promoter) were used (al-Ubaidi et al. 1992; Beltran et al. 2010 Beltran et al. , 2012 . Subretinal injections were performed with a subretinal cannula as previously reported (Komaromy et al. 2006; Beltran et al. 2010) , and volumes injected (70 -150 mL) were adjusted to the dog's age and globe size, aiming to produce a bleb that covered 1/5-1/4 of the retinal surface.
Initial RPGR Gene Therapy Failures and Complications
The first viral vector constructs that were developed and tested in XLPRA1 dogs included a shortened version of the canine RPGR ex1-ORF15 cDNA (cshort RPGR ex1-ORF15 ). The decision to use this shortened RPGR transgene, which had 708 bp removed in frame from the purine-rich region of exon ORF15, was made to circumvent the DNA packaging restric- tion of the AAV capsid (,4.7 kb) in the event that a knockdown construct (small hairpin RNA or ribozyme) should need to be added to correct the XLPRA2 disease. This strategy was based on prior evidence that similar in-frame truncation of murine exon ORF15 did not eliminate its function (Hong et al. 2005) . Five XLPRA1-affected dogs (four hemizygous males and homozygous mutant female) received, at 26 -28 weeks of age (before the onset of retinal degeneration), a 150 mL subretinal injection of either an AAV2/5-mOP-cshortRPGR or AAV2/5-hIRBP-cshortRPGR ex1-ORF15 vector preparation (viral titer: 1.5 Â 10 11 vg/mL), or balanced salt solution. At 5-7 wk postinjection retinal examination revealed multifocal hyperreflective lesions in the treated area of five out of the six eyes that received either of the two vectors. Noninvasive imaging by optical coherence tomography showed disrupted lamination, which represented photoreceptor rosettes on histologic examination (Fig. 2) (Beltran et al. 2011 (Beltran et al. , 2012 . The mechanism by which transduction of photoreceptors with a shortened canine RPGR ex1-ORF15 cDNA led to these complications was not further investigated, and it was decided instead to focus only on the gene augmentation strategy by developing and testing a viral vector that would carry instead the full-length RPGR ex1-ORF15 transgene.
Gene Augmentation with Full-Length Human RPGR ex1-ORF15 Prevents Disease Onset in the XLPRA1 Model
With the goal of accelerating translation of gene therapy to clinical trials, we decided to include the human rather than the canine full-length RPGR ex1-ORF15 in the new viral constructs. In addition, availability of antibodies directed against human RPGR (that do not crossreact with the canine isoform) would allow monitoring of therapeutic transgene expression. An AAV2/5 construct including the hRPGR ex1-ORF15 transgene under the control of the hIRBP promoter was subretinally injected in two XLPRA1 dogs at 28 weeks of age (before the onset of photoreceptor loss). Dogs were monitored by noninvasive confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography until 77 weeks of age (well after the start of retinal degeneration). Topographical mapping of the outer nuclear layer showed increased thickness in the treated region that remained within the range seen in wild-type dogs, while significant thinning was seen in the untreated region of the same eye or in the fellow, balanced salt solution-injected control eye (Fig. 3A,B) . In addition, improved backscatter signal originating from the inner/ outer segment layer was also detectable in the treated area (Beltran et al. 2012) . Histological analysis confirmed the rescue of photoreceptors within the bleb area where RPGR transgene was expressed, as evidenced by an increased number of photoreceptor cells, preserved inner and outer segment structure, and absence of rod opsin and R/G opsin mislocalization (Fig. 4A-C) . This positive effect on the outer retina was also associated with improved structure of the outer plexiform layer, bipolar cells, and a lack of reactivity of Müller cells (the major glial cell population in the retina) (Fig. 4D -F) . These results suggest that early intervention with corrective gene augmentation can prevent the onset of photoreceptor loss and impede deleterious secondary remodeling events in the inner retina. The successful outcome in the XLPRA1 model led us to test whether RPGR gene augmentation alone could also positively alter the course of photoreceptor degeneration in the earlyonset and more rapidly progressive XLPRA2 disease. An AAV2/5 construct including the hRPGR ex1-ORF15 transgene under the control of the hIRBP promoter, and one with the hGRK1 promoter, were each subretinally injected in one XLPRA2 dog at 5 weeks of age (after disease onset, but before the peak of cell death; outer nuclear layer near normal thickness). Fellow eyes were subretinally injected with balanced salt solution. Similar longitudinal analysis (up to 36 weeks of age) of outer nuclear layer thickness from spectral-domain optical coherence tomography-derived topographical maps illustrated a potent rescue of photoreceptors in the treated region with the AAV2/5-hIRBP-hRPGR ex1-ORF15 vector (Fig. 3C,D) , which was confirmed histologically (Fig. 5) .
Treatment corrected the mislocalization of opsins, improved expression of presynaptic markers, resulted in normal length and arborization of bipolar cell dendrites, and prevented Müller cell gliosis. Although structural preservation appeared to be more pronounced with the con- www.perspectivesinmedicine.org struct that included the hIRBP rather than the hGRK1 promoter, both viral vectors rescued photoreceptor-and postreceptoral electroretinogram function (Beltran et al. 2012) . Comparative studies including higher numbers of animals and dose groups are warranted to adequately establish which of these two promoters is optimal.
AAV2/5-hIRBP-hRPGR ex1-ORF15 was also delivered to three 12-wk-old XLPRA2 dogs at mid-stage disease. At this age, the outer nuclear layer thickness is 70% of normal, retraction of rod bipolar cells has begun, and there is increased reactivity of Müller cells (Beltran et al. 2006) . This is right after the peak of photoreceptor cell death and just before the beginning of the "chronic" phase of cell death, during which numerous proapoptotic and prosurvival genes are differentially expressed (Genini et al. 2013) . Dogs were regularly evaluated by noninvasive retinal imaging (scanning confocal laser ophthalmoscopy and spectral-domain optical coherence tomography) and electroretinography at 39 and 42 weeks of age, respectively. Although better rescue was achieved in an agematched XLPRA2 dog treated at five weeks of age (early disease stage), both increased outer nuclear layer thickness in the bleb area and improved electroretinogram function in the treated eye of all three dogs suggest that gene therapy intervention may be beneficial even in retinal areas that have lost .30% of their photoreceptors . Ongoing studies are assessing the efficacy of therapeutic intervention at more advanced stages of disease, and whether a long-term beneficial effect can be sustained (Beltran et al. 2014b) .
Positive response to gene augmentation (alone) in the early onset and rapidly progressive XLPRA2 disease challenges the original assumption that the causative frameshift mutation leads to photoreceptor cell loss through toxic gain-of-function of the mutant RPGR ex1-ORF15 isoform. A more plausible hypothesis might be that the XLPRA2 mutation results in a loss-of-function that severely impairs photoreceptor maturation and survival, whereas the XLPRA1 disease may be caused by a hypomorphic mutation that impairs longterm rod and cone viability. While these preclinical findings in two naturally occurring large animal models of RPGR-XLRP provide confidence that a similar RPGR gene augmentation strategy may be effective and sufficient in treating patients with a wide variety of RPGR mutations, one must remain open to the possibility that a subset of mutations may cause photoreceptor death via a toxic gain-of-function mechanism, and would require instead a combined gene knockdown and gene replacement strategy.
CONCLUDING REMARKS
Availability of two complementary canine models that recapitulate distinct spatiotemporal features of the phenotypes reported in human RPGR-XLRP patients has enabled us to establish initial proof of concept that a corrective gene augmentation approach may be sufficient to both prevent and stop the degenerative process of rods and cones. These results have provided invaluable information about the viral constructs currently being considered. Indeed, there was initially concern that fine-tuning of the levels of RPGR transgene expression in photoreceptors may be required via supposedly less "active" promoters (e.g., the RGPR promoter [Shu et al. 2012] ) than the ones currently used. Yet, the potent hRPGR immunolabeling that was observed with hIRBP and hGRK1 promoters was not limited to the connecting cilium region of transduced canine rods and cones, thus suggesting that some degree of hRPGR ex1-ORF15 overexpression is tolerable and does not induce measurable cytotoxicity. A similar conclusion can be inferred on the basis of the normal retinal phenotype reported in transgenic mouse overexpressing RPGR ORF15 .
These initial proof-of-concept studies in large animals are very encouraging but will need to be monitored over a longer time period. Indeed, recent evidence in patients as well as in dogs treated by gene augmentation for the RPE65 form of Leber congenital amaurosis showed that, despite persistent functional rescue, ongoing photoreceptor loss continues . Ongoing studies in mu-tant dogs should also identify the latest stage of disease that can still respond to gene therapy. Careful extrapolation of these stages from dogs to humans could provide valuable inclusion criteria for the recruitment of patients to future clinical trials. Assessing the effects of RPGR gene augmentation in wild-type dogs also needs to be investigated in preparation for investigational new drug-enabling preclinical safety studies. RPGR overexpression in the wild-type retina will also inform as to whether similar gene therapy intervention could be safely considered for some carrier female patients. Finally, pursuing detailed phenotypic characterization of XLRP patients (Jacobson et al. 1997; Lorenz et al. 2003; Aleman et al. 2007; Huang et al. 2012 ) is necessary to establish valid outcome measures of therapeutic efficacy for future human clinical trials. A patent application on AAV-mediated gene therapy for RPGR X-linked retinal degeneration has been filed (PCT/US2013/022628). W.W.H. and the University of Florida have a financial interest in the use of AAV therapies, and own equity in a company (AGTC Inc.) that might, in the future, commercialize some aspects of this work.
